<- Go Home
XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Market Cap
$4.6M
Volume
6.8K
Cash and Equivalents
$3.1M
EBITDA
-$3.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$6.71
52 Week Low
$1.11
Dividend
N/A
Price / Book Value
1.52
Price / Earnings
-2.21
Price / Tangible Book Value
1.62
Enterprise Value
$1.6M
Enterprise Value / EBITDA
-0.48
Operating Income
-$3.3M
Return on Equity
29.36%
Return on Assets
-33.14
Cash and Short Term Investments
$3.1M
Debt
$83.7K
Equity
$2.7M
Revenue
N/A
Unlevered FCF
-$1.8M
Sector
Pharmaceuticals
Category
N/A